

## FORM 7

### MONTHLY PROGRESS REPORT

**Name of Listed Issuer:** Better Plant Sciences Inc. (the “Issuer”).

**Trading Symbol:** PLNT

**Number of Outstanding Listed Securities:** 186,040,905 common shares (plus 87,782,378 common shares reserved for issuance in the form of 68,290,717 warrants and 19,491,661 options).

**Date:** January 7, 2021

#### **Report on Business**

1. **Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

In December 2020, the Issuer announced:

- a) its wholly owned subsidiary Jusu Wellness Inc. launched eight new Jusu juices which are currently available at the Cadboro Bay Jusu Bar location and will later be available online;
  - b) its majority owned subsidiary Neonmind Biosciences Inc. (“NeonMind”) obtained a receipt for final prospectus for an initial public offering for the sale of up to 46,000,000 units at \$0.10 per units to generate gross proceeds of up to \$4,600,000 (the “NeonMind IPO”), in conjunction with a conditional approval for listing on the Canadian Securities Exchange;
  - c) the NeonMind IPO closed as oversubscribed, fulfilling its entire allotment and over-allotment option;
  - d) the Issuer holds 33,313,500 shares in the capital of NeonMind of its 112,430,500 issued and outstanding shares; and
  - e) NeonMind began trading on the CSE on January 4, 2021 under the stock symbol “NEON”..
2. **Provide a general overview and discussion of the activities of management.**  
Please see Item 1 above.
  3. **Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**  
Please see Item 1 above.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Please see Item 1 above.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Please see Item 1 above.

8. Describe the acquisition of new customers or loss of customers.

Please see Item 1 above.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Please see Item 1 above.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
Special Warrants	2,613,635	December 3, 2020: 2,613,635 special warrants issued pursuant to a private placement at a price of \$0.055 per special warrant. Each special warrant is exercisable without further payment into one unit of the Issuer. Each unit consists of one common share in the capital of the Issuer and one share purchase warrant exercisable at \$0.07 for a period of six (6) months from the date of issuance for an additional common share in the capital of the Issuer	Net proceeds of \$143,750 to be used as set out in the Prospectus Supplement
Common Shares	2,178,571	December 11, 2020: 2,178,571 common shares issued pursuant to the conversion of warrants at a price of \$0.08 per share.	Proceeds of \$174,285.68 to be used for general working capital
Units	2,613,635	December 15, 2020 2020: 2,613,635 units issued pursuant to the conversion of the 2,613,635 special warrants issued on December 3, 2020. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.07 until June 3, 2021.	Not applicable.
Common Shares	2,295,454	December 16, 2020: 2,295,454 common shares issued pursuant to the conversion of warrants at a price of \$0.07 per share.	Proceeds of \$160,681.78 to be used for general working capital

Stock Options	4,160,000	December 17, 2020: 4,160,000 stock options granted to various directors, officers, employees, and consultants at an exercise price of \$0.17 per common share for a maximum period of 5 years (or earlier in accordance with the Issuer's stock option plan).	Not applicable.
Common Shares	80,000	December 18, 2020: 80,000 common shares issued pursuant to the conversion warrants at a price of \$0.08 per share	Proceeds of \$6,400 to be used for general working capital
Common Shares	400,000	December 24, 2020: 400,000 common shares issued pursuant to the conversion of options at a price of \$0.10 per share	Proceeds of \$40,000 to be used for general working capital

*(1) State aggregate proceeds and intended allocation of proceeds.*

**15. Provide details of any loans to or by Related Persons.**

None.

**16. Provide details of any changes in directors, officers or committee members.**

None.

17. **Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic. It has adversely affected global workforces, economies, and financial markets, triggering an economic downturn and is expected to impact many retail businesses. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak nor its effects on the Company's business or operations at this time.

The Issuer implemented travel restrictions for work related travel, and imposed self-isolation for employees with symptoms of sickness or returning from international travel. The Issuer also cancelled live multi person events such as in store pop ups and influencer events until further notice.

The Issuer is well-positioned to take advantage of the growing importance placed on physical and mental health and wellbeing, and the rising demand for high-quality, natural products that support this.

The Issuer intends to increase revenues through products that are in high and sustainable consumer demand, drawing on existing, stability-tested formulas to bring these to market under new and existing brands. It has added several hand sanitizer products to its Urban Juve brand, initiated research into topicals that may fight infectious diseases and continues with production plans for its immune boosting mushroom coffee line.

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

**Dated** January 7, 2021.

Penny White  
Name of Director or Senior Officer

"Penny White"  
Signature

Chief Executive Officer and  
President  
Official Capacity

<b>Issuer Details</b> <b>Name of Issuer</b> Better Plant Sciences Inc.	<b>For Month End</b> November 2020	<b>Date of Report</b> <b>YY/MM/DD</b> 20/12/03
<b>Issuer Address</b> Suite 200, 1238 Homer Street		
<b>City/Province/Postal Code</b> Vancouver, British Columbia V6B 2Y5	<b>Issuer Fax No.</b> N/A	<b>Issuer Telephone No.</b> 833.514.2677
<b>Contact Name</b> Penny White	<b>Contact Position</b> President, CEO, and Director	<b>Contact Telephone No.</b> 833.514.2677
<b>Contact Email Address</b> <a href="mailto:penny@betterplantsciences.com">penny@betterplantsciences.com</a>	<b>Web Site Address</b> <a href="http://www.betterplantsciences.com">www.betterplantsciences.com</a>	